医疗保险开始2026年试点让受益人每年花费高达500美元购买大麻衍生CBD,引发了关于安全性和监管的争论. Medicare begins 2026 pilot letting beneficiaries spend up to $500 yearly on hemp-derived CBD, sparking debate over safety and regulation.

从2026年4月开始,Medicare将启动一个试点方案,使受益者每年最多能将500美元用于来自大麻的《生物多样性公约》产品,引发关于公共健康风险和监管不一致的辩论。 Starting in April 2026, Medicare will launch a pilot program allowing beneficiaries to use up to $500 annually on hemp-derived CBD products, sparking debate over public health risks and regulatory inconsistencies. 虽然支持者强调慢性疼痛、睡眠和焦虑的潜在好处,但批评者警告倡议可能会使老年人暴露在未经证实、监管不严的产品中,产品缺乏标准化的能力、纯度或临床鉴定。 While proponents highlight potential benefits for chronic pain, sleep, and anxiety, critics warn the initiative may expose older adults to unproven, poorly regulated products lacking standardized potency, purity, or clinical validation. 该方案与林业发展局对药品的严格要求形成对照,使人们对破坏科学标准和阻碍适当药物开发表示关切。 The program contrasts with strict FDA requirements for pharmaceuticals, raising concerns about undermining scientific standards and discouraging proper drug development. 虽然试点可以生成真实世界数据,但产品质量不一致可能会限制其可靠性。 Although the pilot could generate real-world data, inconsistent product quality may limit its reliability. 结果可能决定大麻素是作为药品还是作为不受管制的健康物品处理。 The outcome may shape whether cannabinoids are treated as medicine or unregulated wellness items.